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Background. Breast cancer is the most common cancer in women. Disparities in some characteristics of breast cancer patients
and their survival data for six randomly selected states in the US were examined. Materials and Methods. A probability random
sampling method was used to select the records of 2,000 patients from each of six randomly selected states. Demographic and disease
characteristics were extracted from the Surveillance Epidemiology and End Results (SEER) database. To evaluate relationships
between variables, we employed a Cox Proportional Regression to compare survival times in the different states. Results. Iowa had
the highest mean age of diagnosis at 64.14 years (SE = 0.324) and Georgia had the lowest at 57.97 years (SE = 0.313). New Mexico
had the longest mean survival time of 189.09 months (SE = 20.414) and Hawaii the shortest at 119.01 (SE = 5.394) months, a
70.08-month difference (5.84 years). Analysis of stage of diagnosis showed that the highest survival times for Whites and American
Indians/Alaska Natives were for stage I cancers. The highest survival times for Blacks varied. Stage IV cancer consistently showed
the lowest survival times. Conclusions. Differences in breast cancer characteristics across states highlight the need to understand
differences between the states that result in variances in breast cancer survival.

1. Introduction
Breast cancer is a worldwide public health concern within
many countries, including the United States (US) which has
experienced a recent 20% increase in breast cancer diagnosis.
Breast cancer is the most prevalent type of cancer (29%) in
women in the US. Additionally, breast cancer is the most
commonly diagnosed malignancy among women in the US,
accounting for nearly one out of every three diagnosed
malignancies [1, 2]. Between 1975 and 1995, breast cancer
incidence in women increased from 81 out of 100,000 personyears to 97 out of 100,000 person-years (Althuis, Dozier,
Anderson, Devesa, and Brinton, 2005). Secondly, the US had

a 29% rate of breast cancer in women, with women over the
age of 50 years having the highest incidence ([3]; Kohler et al.,
2015). Furthermore, it is estimated that one in eight women
living in the US will develop breast cancer in their lifetime [1].
In 2013, there were 232,340 cases of invasive breast cancer in
women in the US and 39,620 associated deaths [1]. In the US,
over three million women are currently living with a history
of invasive breast cancer, with 40% of cases occurring in
women over 65 years of age and 20% among women younger
than 50 years of age [4]. Therefore, the increase in breast
cancer incidence and the cancer-related complications have
remained a significant public health issue within the US over
the last few decades.
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Prevention and Treatment. Early detection is the primary
focus of breast cancer prevention efforts in most settings. In
2015, the American Cancer Society (ACS) reported that 66%
of women aged 40 years and older had a mammogram within
the past two years [5], an increase from 2010 where it was
estimated that at least half of all women in the US between
ages 40 and 74 years had received a mammogram [6].
The National Breast and Cervical Cancer Early Detection
Program (NBCCEDP) is a program developed by the Centers
for Disease Control and Prevention (CDC) to increase breast
and cervical cancer screening rates among economically
disadvantaged women. In the years 2011 to 2012, NBCCEDP
screened 549,043 underserved women between the ages of
40 and 64 years. NBCCEDP screened about 10% of eligible
women with screening rates ranging from 3.2 to 52.8% of
the eligible population [7]. Overall, the program screened
over half a million women; however, most eligible women
remained unscreened for breast cancer and may require
increased outreach efforts [7]. Mammogram use was lowest
among American Indians and Alaska Natives at 36% [7, 8].
Research shows that 43.5% of the 137,274 eligible women had
at least one mammogram screening. Additionally, women
66 to 74 years old were more likely to get mammography
screening compared to those 85 to 100 years or older (57.2%
versus 15.2%, resp.; 𝑝 < 0.001) [9]. Further research shows
that 50.1% of Black women and 40.8% of White women aged
65–74 years received either no or one screening mammogram
from 2005 to 2008 [10].
Health Disparities. There have been major improvements in
screening and treatment; however, there remain racial and
ethnic differences in breast cancer screening and mortality.
As of 2014, the rates of breast cancer have increased for
Black Americans and have decreased for Hispanics [1]. The
public health community has focused on increasing the breast
cancer screening rates of ethnic and racial minorities and
has had some success increasing the rates of breast cancer
screening for Black Americans and some Hispanic groups,
with the exception of Mexican Americans [11]. Ethnicity and
race are found to be major predictors of breast cancer prognosis and incidence; social, environmental, and hereditary
determinants directly affect the development of breast cancer
[3, 6, 8, 12, 13].
Black women have an increased risk for more aggressive
forms of breast cancer, such as estrogen receptor negative
tumors, which frequently do not respond well to current
therapies [6]. Black women under the age of 50 years also
experience higher rates of breast cancer compared to White
women of comparable ages. Additionally, Black and White
women who had one mammogram annually had a lower 10year mortality than those who received screening irregularly
or biennially [10]. When diagnosed at the same stage, Black
women face higher rates of mortality associated with breast
cancer than White women and are more likely to be diagnosed at advanced stages of the disease [14]. Mammogram
use is 33% lower among immigrants who migrated to the US
within the last 10 years [8]. Many of these immigrants lack
health insurance and have lower education levels and limited
income, which can contribute to lower screening rates, and
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women who experience inconsistent screening rates have a
shorter 10-year survival time after breast cancer diagnosis
[8, 11].
Structural, organizational, and political factors further
exacerbate issues of racial and ethnic disparities in cancer
mortality [14]. Issues of poverty, poor access to care, poor
transportation, low or no income, and lack of health insurance increase the chances of a poor prognosis and lower
screening rates [14]. Additionally, some groups are diagnosed
with varying types of breast cancer. For example, estrogen
receptor negative breast cancers have decreased across all
ethnicities, but rates of estrogen receptor positive breast
cancer have increased in young White women, older Hispanic
women between the ages of 60 and 69 years, and all groups of
Black Americans except the eldest groups [14, 15].
Some variations among populations of breast cancer
patients are a result of state-level policy or environmental
risks; because of these differences it is important to know
what differences are present from state to state. This study
uses cancer registries from six randomly selected states to
perform statistical analyses. The registries are from Georgia,
New Mexico, Hawaii, Connecticut, Iowa, and California.
Between years 1999 and 2011, New Mexico and Iowa had
an interval of 107.2 to 118.3 breast cancer cases per 100,000
people; Hawaii and Connecticut had between 126.9 and 141.4
cases per 100,000; and Georgia and California had 126.9 to
141.4 cases per 100,000 people. Death rates in each state
ranged from 15.5 to 22.6 per 100,000. Hawaii, Connecticut,
and New Mexico have death rates of 15.5 to 19.1 per 100,000;
Iowa and California have rates from 19.2 to 21.1 per 100,000;
and finally, Georgia have rates of 21.2 and 22.6 per 100,000
breast cancer cases [16]. In this paper, we provide the
observed numbers of breast cancer cases and deaths in the US
from 1973 to 2011 for six states randomly selected out of nine
recorded states, as well as a broad summary of breast cancer
incidence and survival times.

2. Materials and Methods
The study used data from the Surveillance Epidemiology and
End Results (SEER) database (1973–2011). The SEER database
started collecting data in 1973 for about 10% of the US population from nine states. Currently, the SEER program collects
and publishes cancer incidence and survival information
from cancer registries covering 28% of the US population
[17]. The SEER website includes data from twenty populationbased registries across varying states and territories. For this
study, only data collected from the years 1973 to 2011 will be
evaluated from each of the six states: California, Connecticut,
Georgia, Hawaii, Iowa, and New Mexico. The representative
probability sample data were randomly selected from the
six SEER registries, and the selected data were summarized
for information on stage of cancer, overall survival, and the
lifetime probability of developing breast cancer.
Inclusion criteria for the present study are female gender,
first and primary diagnosis of stages I, II, or III breast cancer,
no previous cancer(s) being registered, and age 20 years or
older. A participant’s contribution to the person-years at risk
began from the date of breast cancer diagnosis to the date of
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Figure 1: Female breast cancer cases (𝑛 = 2,000) randomly selected
from the six states (darker blue color represents the selected states).

death or loss to follow-up, whichever occurred first. Women
diagnosed with breast cancer at autopsy were excluded. Since
breast cancer is uncommon in males, only female cases
were included in this study. The SEER-coded categories of
registry ID (REG) were used to classify participants into six
mutually exclusive categories. Simple random sampling was
used to select 2,000 cases from each registry. Information
on the methods used for random sampling can be found
in previously published literature by Khan et al. [18–21]. In
addition, we used subject demographic information (age at
diagnosis, marital status, race, and ethnicity) and survival
time from the SEER dataset for statistical analysis. Data
regarding other socioeconomic factors, such as income and
health insurance status, were not available.
A total of 12,000 women with breast cancer were included
in the analysis (for each state’s registry 𝑛 = 2,000, Figure 1)
and individual survival time is defined by t, where t contains
12,000 survival data points and 𝑛 = 2,000 for each state.
Survival analysis accounted for both censored (patients who
survived till the end of SEER registry’s cutoff date) and
uncensored (any patient who died within the SEER registry’s
cutoff date) data. Survival time was calculated in months
using the Cox proportional hazards model, adjusting for
age at diagnosis, race, ethnicity, and marital status. Cox
proportional hazards models generated the adjusted hazard
ratio and their 95% confidence intervals (CI). Data analysis
was conducted using SPSS software (IBM SPSS for Windows
version 20, 2011) and SAS software version 9.4.

3. Results and Discussion
Using a probability sampling method, which is simple random sampling method, 2,000 patients were selected from
six state cancer registries (California, Connecticut, Georgia,
Hawaii, Iowa, and New Mexico). Tables 1 and 2 contain
the descriptive statistics. Table 1 shows diagnosis (in years),
survival time (in months), and marital status at the time of
diagnosis. Iowa has the highest mean age of diagnosis, 64.14
years (SE = 0.324), and then Connecticut, California, New
Mexico, Hawaii, and Georgia, with mean age of diagnosis
being 62.51 (SE = 0.320), 61.42 (SE = 0.564), 61.3 (SE =
0.316), 59.72 (SE = 0.305), and 57.97 (SE = 0.313),

respectively. Table 1 also indicates that Iowa has the older
stage at diagnosis for breast cancer patients followed by
Connecticut. Hawaii and Georgia have the lowest ages of
breast cancer diagnosis. The 25th and 50th quartiles of
age at diagnosis ranged from 48–53 to 57–65 years of age,
respectively, for all six states.
Mean survival days (in months) were also calculated and
stratified by each cancer registry. New Mexico reported the
longest mean survival time of 189.09 months (SE = 20.414),
and Hawaii reported the shortest mean survival time of 119.01
(SE = 5.394) months, representing a 70.08-month difference
(5.84 years). The 25th and 50th quartiles of survival times
generally ranged from 33–41 to 83–96 months, respectively,
for all six states.
Table 2 shows the frequency and percentage of each
race, ethnicity, and marital status for each of the six states
studied. Most participants were married with widowed being
the second most common relationship status, and separated
women were the smallest group. Married women made up
over half of the women with a breast cancer diagnosis,
ranging from 52.95% in Connecticut to 59.6% in Hawaii.
We have stratified data by race and 5-year-time intervals
for age at diagnosis and obtained the following summary
statistics for six states: in California during 1973–1980, 61.50
years (SD = 13.68) was the mean age of diagnosis for
White patients, compared to 57.52 years (SD = 14.47) for
Black patients and 47.71 years (SD = 18.09) for American
Indians/Alaska Natives. Between 1981 and 1985, American
Indians/Alaska Natives had a mean age of diagnosis of 54.18
years (SD = 13.34) for diagnosis compared to 52.45 years
(SD = 15.51) for Blacks and 63.42 years (SD = 14.34)
for Whites. During 1986–1990, Whites had a mean age of
diagnosis of 61.57 years (SD = 15.02) as their mean age of
diagnosis compared to 55.44 years (SD = 18.14) for Blacks
and 53.42 years (SD = 14.99) for American Indians/Alaska
Natives. During 1991–1995, American Indians/Alaska Natives
had a mean age of diagnosis of 55.56 years (SD = 15.25),
compared to 59.76 years (SD = 14.21) for Blacks and 62.19
years (SD = 13.86) for Whites. During 1996–2000, American
Indians/Alaska Natives had a mean age of diagnosis at 62.31
years (SD = 15.39) compared to 55.78 years (SD = 11.70)
for Blacks and 61.54 years (SD = 12.65) for Whites. During
2001–2005, Whites had a mean age of diagnosis at 60.45
years (SD = 13.79), compared to 55.21 years (SD = 14.52)
for Blacks and 57.43 years (SD = 12.77) for American
Indians/Alaska Natives. During 2006–2011, Whites had a
mean age of diagnosis at 62.47 years (SD = 13.93), compared
to 64.53 years (SD = 11.99) for Blacks and 58.54 years (SD =
13.44) for American Indians/Alaska Natives.
In Connecticut between 1973 and 1980, Whites had
61.56 years (SD = 12.42) as the mean age of diagnosis
compared to 47.88 years (SD = 16.83) for Blacks while no
cases were reported for American Indians/Alaska Natives.
During 1981–1985, American Indians/Alaska Natives had a
mean age of diagnosis of 59 years with only one patient
compared to 61.50 years (SD = 12.72) for Blacks and 62.86
years (SD = 14.79) for Whites. During 1986–1990, Whites
had a mean age of 63.39 years (SD = 14.29) compared
to 58.92 years (SD = 14.94) for Blacks and 61 years
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Table 1: Age at diagnosis and survival time for female breast cancer patients (𝑛 = 2,000).

Age at diagnosis (years)

Survival time (months)

Statistics
Mean
SE
Median
Quartiles
Mean
SE
Median
Quartiles

California
61.42
0.564
60
50, 60, 71
181.12
17.882
96
41, 96, 175

Connecticut
62.51
0.320
62
51, 62, 74
165.18
16.489
87
35, 87, 167

Georgia
57.97
0.313
57
48, 57, 68
155.13
15.739
84
34, 84, 158

Hawaii
59.72
0.305
59
49, 59, 70
119.01
5.394
91
37, 91, 167

Iowa
64.14
0.324
65
53, 65, 76
152.76
14.115
88
38, 88, 167

New Mexico
61.30
0.316
61
51, 61, 72
189.09
20.414
83
33, 83, 158

Table 2: Race, ethnicity, and marital status for female breast cancer patients (𝑛 = 2,000).
CA
Race
White
1589
Black
161
American Indian or Alaskan Native
4
Asian or Pacific Islander
230
Other
8
Unknown
8
Ethnicity
Hispanic
140
Non-Hispanic
1860
Marital status
Single
293
Married
1062
Separated
25
Divorced
193
Widowed
370
Unknown
57

%

CT

%

GA

%

HI

%

IA

%

NM

%

79.45
8.05
0.2
11.5
0.4
0.4

1876
105
1
8
4
6

93.8
5.25
0.05
0.4
0.2
0.3

1403
560
3
31
0
3

70.15
28
0.15
1.55
0
0.15

604
17
4
1366
4
5

30.2
0.85
0.2
68.3
0.2
0.25

1977
18
0
2
0
3

98.85
0.9
0
0.1
0
0.15

1894
17
75
8
2
4

94.7
0.85
3.75
0.4
0.1
0.2

7
93

72
1928

3.6
96.4

54
1946

2.7
97.3

78
1922

3.9
96.1

8
1992

0.4
99.6

533
1467

26.65
73.35

14.65
53.10
1.25
9.65
18.50
2.85

233
1059
85
173
375
75

11.65
52.95
4.25
8.65
18.75
3.75

252
1095
19
235
342
57

12.6
54.75
0.95
11.75
17.1
2.85

219
1192
15
186
328
60

10.95
59.6
0.75
9.3
16.4
3

145
1165
8
138
512
32

7.25
58.25
0.4
6.9
25.6
1.6

199
1082
10
159
364
186

9.95
54.1
0.5
7.95
18.2
9.3

for American Indians/Alaska Natives with only one patient
reported. During 1991–1995, there were no cases reported for
American Indians/Alaska Natives, while the mean age for
Blacks was 53.60 years (SD = 15.33) compared to 63.15 years
(SD = 14.81) for Whites. Between 1996 and 2000, Whites
had a mean age of diagnosis at 63.46 years (SD = 14.73)
compared to 55.47 years (SD = 14.62) for Blacks and 76.00
years for American Indians/Alaska Natives with only one
patient. During 2001–2005, there were no cases reported for
American Indians/Alaska Natives, while the age of diagnosis
for Blacks was 63.74 years (SD = 15.17) compared to 62.93
years (SD = 14.38) for Whites. During 2006–2011, Whites
had a mean age of diagnosis at 61.90 years (SD = 14.13)
compared to Blacks at 61.81 years (SD = 15.14) and American
Indians/Alaska Natives at 59.17 years (SD = 14.63).
In Hawaii between 1973 and 1980, White patients reported
54.69 years (SD = 13.10) as the mean age of diagnosis
compared to 64.00 years (SD = 1.414) for Blacks and
53.54 years (SD = 13.46) for American Indians/Alaska
Natives. During 1981–1985, American Indians/Alaska Natives
reported 54.85 years (SD = 12.47) for their age of diagnosis
compared to 58.00 years (SD = 16.971) for Blacks and 58.56

years (SD = 15.47) for Whites. During 1986–1990, Whites
had a mean age of diagnosis at 58.70 years (SD = 15.06)
compared to 42.00 years (SD = 7.07) for Blacks and 59.25
years (SD = 12.82) for American Indian/Alaska Natives.
During 1991–1995, American Indians/Alaska Natives had a
mean age of diagnosis at 58.09 years (SD = 13.07) compared
to 43.00 years for Blacks with only one patient reported
and 61.30 years (SD = 13.65) for White patients. During
1996–2000, Whites reported 62.07 years (SD = 13.96) as their
mean age of diagnosis compared to 53.00 years for Blacks with
only one patient reported and 60.30 years (SD = 13.66) for
American Indians/Alaska Natives. Between 2001 and 2005,
American Indians/Alaska Natives reported 61.57 years (SD =
14.14) as the mean age of diagnosis compared to 51 years for
Blacks with one patient reported and 62.11 years (SD = 14.13)
for Whites. During 2006–2011, Whites reported 61.10 years
(SD = 11.67) compared to 46.38 years (SD = 9.84) for Blacks
and 61.09 years (SD = 13.06) for American Indians/Alaska
Natives as the mean age of diagnosis.
In Iowa, during 1973–1980, Whites reported age 64.64
years (SD = 14.45) as mean age of diagnosis compared
to 68.50 years (SD = 26.16) for Blacks while no cases
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were reported for American Indians/Alaska Natives. Between
1981 and 1985, no cases were reported for American Indians/Alaska Natives and Blacks while Whites’ mean age of
diagnosis was 64.24 years (SD = 14.26). During 1986–1990,
Whites had a mean age of diagnosis of 65.83 years (SD =
14.46) compared to age 64 years for Blacks with one
patient reported and no patients reported for American
Indians/Alaska Natives. During 1991–1995, no cases were
reported for American Indians/Alaska Natives while age
52.67 years (SD = 26.08) was reported for Blacks and 63.32
years (SD = 14.58) for Whites. During 1996–2000, Whites
had a mean age of diagnosis at 64.70 years (SD = 14.96),
while no cases were reported for Blacks during that time or
American Indians/Alaska Natives. During 2001–2005, there
were also no cases reported for American Indians/Alaska
Natives; Blacks reported a mean of diagnosis at age 56.33 years
(SD = 8.35) compared to Whites at age 64.30 years (SD =
14.64). Between 2006 and 2011, Whites had a mean age of
diagnosis at 63.29 years (SD = 13.88) compared to 50.17 years
(SD = 13.73) for Blacks and age 66 years among American
Indians/Alaska Natives with only one patient reported.
In New Mexico, during 1973–1980, Whites had a mean
age of diagnosis at 60.65 years (SD = 14.29) compared
to 53.25 years (SD = 5.31) for Blacks and 57.50 years
(SD = 17.05) for American Indians/Alaska Natives. During
1981–1985, American Indians/Alaska Natives had a mean
age of diagnosis at 48.33 years (SD = 20.20) compared
to 51 years for Blacks with only one patient reported and
60.57 years (SD = 14.98) for Whites. During 1986–1990,
Whites reported a mean age of diagnosis at 62.23 years
(SD = 14.50); Blacks reported no cases at that time and
American Indians/Alaska Natives reported 53.60 years (SD =
16.33) as the age of diagnosis. During 1991–1995, American
Indians/Alaska Natives reported age 65 years (SD = 13.10)
compared to 80 years (SD = 7.07) for Blacks and 59.98 years
(SD = 14.93) for Whites. During 1996–2000, Whites reported
61.28 years (SD = 13.93) as the mean age of diagnosis
compared to 47.67 years (SD = 8.08) for Blacks and 60.88
years (SD = 9.52) for American Indian/Alaska Natives.
During 2001–2005, American Indians/Alaska Natives had a
mean of 55.59 years (SD = 11.03) compared to Blacks at
61.67 years (SD = 19.55) and Whites at 62.07 years (SD =
14.16). Between 2006 and 2011, Whites reported a mean age of
diagnosis at 62.66 years (SD = 13.27) compared to Blacks at
44 years (SD = 15.53) and American Indians/Alaska Natives
at 55.15 years (SD = 11.88).
In Georgia, during 1973–1980 Whites had a mean age of
diagnosis at 58.67 years (SD = 13.84) compared to Blacks
at 53.55 years (SD = 15.94) and American Indians/Alaska
Natives at 53 years but with only one patient reported. During
1981–1985, no cases of American Indians/Alaska Natives were
reported for that period; Blacks had a mean age of diagnosis
at 55.20 years (SD = 17.89) compared to Whites at 59.39
years (SD = 15.76). During 1986–1990, Whites had a
mean of 59.34 years (SD = 15.04) compared to Blacks at
52.78 years (SD = 13.84) while no cases were reported for
American Indians/Alaska Natives for that period. During
1991–1995 American Indians/Alaska Natives had a mean
age of 48.50 years (SD = 0.707) compared to 53.95 years

5
(SD = 15.05) for Blacks and 59.64 years (SD = 13.75) for
Whites. During 1996–2000, Whites reported a mean age of
diagnosis at 59.49 years (SD = 12.73) compared to Blacks
at 55.62 years (SD = 15.21) and 55.25 years (SD = 9.91)
for American Indians/Alaska Natives. During 2001–2005,
American Indians/Alaska Natives had 44.00 years (SD =
11.93) as the mean age of diagnosis compared to Blacks
at 52.67 years (SD = 13.44) and Whites at 59.92 years
(SD = 13.51). During 2006–2011, Whites had a mean of 59.44
years (SD = 13.57) for diagnosis compared to 56.37 years
(SD = 12.68) and 49.63 years (SD = 11.56) for American
Indians/Alaska Natives.
Data stratified by race and 5 years’ period for age at
diagnosis gave evidence of change of mean age of diagnosis
across the span of 38 years. In New Mexico during 1973–1980
the mean age of diagnosis for Black patients was 53.25 years
(SD = 5.31), while during 2006–2011 Black patients reported
a mean age of diagnosis of 44 years (SD = 15.53). The White
patients did not have such a difference reporting a mean age
of diagnosis of 60.65 (SD = 14.29) during 1973–1980 and
62.66 (SD = 13.27) during 2006–2011. Hawaii additionally
had similar results reporting mean age of diagnosis of 64.00
(SD = 1.414) for Black patients during 1973–1980 and 46.38
years (SD = 9.84) for Black patients during 2006–2011. White
patients reported 54.69 years (SD = 13.10) as their mean age
of diagnosis during 1973–1980 and 61.10 years (SD = 11.67)
during 2006–2011. Stage 1 cancer at diagnosis had the longest
survival for Whites and American Indians/Alaska Natives in
1986–1990, while Blacks had the longest survival for diagnosis
at stage IIB. In 2001–2005, Stage 1 cancer at diagnosis had
the longest survival for Whites and American Indians/Alaska
Natives, but stage IIIA cancer had the longest survival for
Blacks. Stage IV cancers had the shortest survival times across
all ethnic groups between 1986–1900 and 2001–2005.
Table 3 shows the analysis of Cox proportional hazard
ratio and its corresponding confidence intervals. New Mexico, with the highest mean survival time, was made the
referent group for calculating hazard ratios, adjusting for
states using the Cox Proportional Regression. Hazard ratios
compare the probability of an event occurring in one group
versus another group considering the time elapsed until the
event occurs. Hazard ratios were calculated for five states. The
hazard ratio for California is 0.925 with a 95% confidence
interval (0.842, 1.017), with a 𝑝 = 0.105. The hazard ratio for
Connecticut is 0.991 with a 95% confidence interval (0.903,
1.087), with a 𝑝 = 0.844. The hazard ratio for Georgia is
0.988 with a 95% confidence interval (0.895, 1.091), with a
𝑝 = 0.811. The hazard ratio for Hawaii is 0.786 with a 95%
confidence interval (0.711, 0.869), with a 𝑝 < 0.0001. The
hazard ratio for Iowa is 0.968 with a 95% confidence interval
(0.884, 1.060), with a 𝑝 = 0.484. In survival analysis, the event
under consideration is death, and “alive” status was used as
the censoring variable. The mean survival time for Hawaii was
119.01 months (9.92 years). New Mexico had a longer survival
time of 189.09 months (15.75 years) when compared to the
other states. Breast cancer patients who resided in California,
Connecticut, Georgia, Hawaii, Iowa, and New Mexico had
mean survival times of 181.12 months, 165.18 months, 155.13
months, 119.01 months, 152.76 months, and 189.09 months,
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Table 3: Hazard ratio and confidence intervals.

States

DF

Parameter
estimate

Standard error

Chi-Square

Pr > ChiSq

Hazard ratio

1
1
1
1
1

−0.078
−0.009
−0.012
−0.241
−0.033

0.048
0.047
0.050
0.051
0.046

2.622
0.039
0.057
22.318
0.490

𝑝 = 0.105
𝑝 = 0.844
𝑝 = 0.811
𝑝 < 0.0001
𝑝 = 0.484

0.925
0.991
0.988
0.786
0.968

California
Connecticut
Georgia
Hawaii
Iowa

95% hazard ratio
Confidence limits
Lower limit Upper limit
0.842
0.903
0.895
0.711
0.884

1.017
1.087
1.091
0.869
1.060

Table 4: Hazard ratio and confidence intervals.
States
California
Connecticut
Georgia
Iowa
New Mexico

DF

Parameter
estimate

Standard error

Chi-Square

Pr > ChiSq

Hazard ratio

1
1
1
1
1

0.163
0.232
0.229
0.208
0.241

0.051
0.050
0.053
0.049
0.051

10.400
21.645
18.834
17.990
22.318

𝑝 < 0.001
𝑝 < 0.0001
𝑝 < 0.0001
𝑝 < 0.0001
𝑝 < 0.0001

1.177
1.261
1.257
1.232
1.272

respectively. New Mexico, California, and Connecticut have
the longest survival times.
In Table 4, Hawaii was used for the referent group.
Hawaii had a significantly increased risk of death compared
to California (hazard ratio: 1.177; 95% confidence limits
(1.066–1.300)); Connecticut (hazard ratio: 1.261; 95% confidence limits (1.143–1.390)); Georgia (hazard ratio: 1.257; 95%
confidence limits (1.134–1.394)); Iowa (hazard ratio: 1.232;
95% confidence limits (1.119–1.356)); New Mexico (hazard
ratio: 1.272; 95% confidence limits (1.151–1.406)).
This study’s findings showed that New Mexico reported
the longest mean survival time compared to Hawaii, which
had the shortest mean survival time, demonstrating a fiveyear difference. This suggests that there are potential differences across states that affect survival time.
In 2010, SEER began collecting data on breast cancer
receptor status. The breast cancer subtypes are defined by
joint hormone receptor (HR; estrogen receptor [ER] and
progesterone receptor [PR]) and human epidermal growth
factor 2 (HER2) receptor status. “Not 2010+” reported cancer
patients did not have such data collected. Between 1973 and
1980, American Indians/Alaska Natives experienced longer
survival times for not 2010+ cancers at 221.49 months (SD =
164.73) compared to Blacks at 168.07 months (SD = 133.42)
and Whites at 162.24 months (SD = 138.07). During
1981–1985, American Indians/Alaska Natives again had a
longer survival time for not 2010+ cancers at 186.95 months
(SD = 120.42) compared to Whites at 153.38 months (SD =
118.39) and Blacks at 104.21 months (SD = 111.17). Between
1986 and 1990, American Indians/Alaska Natives had a longer
survival time for not 2010+ cancer at 171.94 (SD = 102.23)
compared to Whites at 164.24 months (SD = 100.19) and
Blacks at 140.09 (SD = 108.83). During 1991–1995, American
Indians/Alaska Natives again experienced a higher survival
time for not 2010+ at 160.44 months (SD = 79.58), compared

95% hazard ratio
Confidence limits
Lower limit Upper limit
1.066
1.143
1.134
1.119
1.151

1.300
1.390
1.394
1.356
1.406

to Whites at 149.81 months (SD = 78.89) and Blacks at
131.07 months (SD = 80.69). During 1996–2000, American
Indians/Alaska Natives had a higher survival time for not
2010+ cancers at 128.60 months (SD = 49.83), compared
to Whites at 121.55 months (SD = 54.77) and Blacks at
116.55 months (SD = 59.65). Between 2001 and 2005,
each ethnic group reported similar survival rates. American
Indians/Alaska Natives reported a slightly longer survival
time for not 2010+ at 87.64 months (SD = 31.94) compared
to Whites at 85.47 (SD = 32.17) and Blacks at 85.25 months
(SD = 32.44). Between 2006 and 2011 more cancer ER
statuses were reported, American Indians/Alaska Natives
reported the highest survival time among not 2010+ cancers
at 42.16 months (SD = 16.33) and lowest survival with
HER2+/HR− at 9.10 months (SD = 7.70). Whites reported
the highest survival time for not 2010+ breast cancer at
42.02 months (SD = 17.39) and the lowest survival for
those diagnoses with HER2+/HR+ at 9.27 months (SD =
6.58). Among Blacks during the same period, the longest
survival time was also among those diagnosed with not 2010+
cancers with 42.28 months (SD = 16.24), with the lowest
survival time being for those diagnosed with triple negative
cancers at 8.94 months (SD = 6.65). There was no stage
of diagnosis reported between 1973–1985 and 2006–2011.
However, between 1986 and 1990 the highest survival for
Whites and American Indians/Alaska Natives was for stage
I cancers. White patient survival time was 185.80 months
(SD = 85.52) while 208.50 months (SD = 83.23) was the
mean survival for American Indians/Alaska Natives. Blacks
reported 173.33 months (SD = 92.43) for stage I but their
highest survival was 257.00 months (SD = 4.24) at stage
IIB. Stage IV cancers had the shortest survival times across
all ethnic groups with 27.68 months (SD = 39.76) for
Whites, 16.22 months (SD = 21.04) for Blacks, and 4 months
for American Indians/Alaska Natives with only one patient
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reported. During 1991–1995, the highest survival reported for
Whites and Blacks was stage I cancers. Whites reported 170.17
months (SD = 68.06) and Blacks reported 155.29 months
(SD = 69.62). However, the American Indians/Alaska
Natives reported highest survival for stage IIIA cancers at
205.67 months (SD = 20.30). Stage IV cancers had the shortest survival times at 32.32 months (SD = 49.54) for Whites,
53.25 months (SD = 92.89) for Blacks, and 55.33 months
(SD = 90.60) for American Indians/Alaska Natives. For
American Indians/Alaska Natives the highest survival time
was among stage IIIA cancers at 205.67 months (SD = 20.30).
Between 1996 and 2000, the highest survival time was among
stage I cancers; for Whites the survival was 134.74 months
(SD = 45.71), 141.77 months (SD = 43.68) for Blacks, and
138.95 months (SD = 41.00) for American Indians/Alaska
Natives. The shortest survival during that period was stage IV
cancers; American Indians/Alaska Natives reported a mean
of 43.11 months (SD = 38.05), 35.64 months (SD = 47.65)
for Whites, and 17.57 months (SD = 16.88) for Blacks.
Between 2001 and 2005, the highest survival time among
Whites and American Indians/Alaska Natives was in stage
I cancer. Whites reported a mean survival time of 102.04
months (SD = 27.82) and American Indians/Alaska Natives
reported 105.47 months (SD = 24.42). Blacks reported the
highest survival rates with stage IIIA cancers at 122.00 months
(SD = 1.414). Stage IV cancers had the shortest survival times
for all ethnic groups during that period, Whites reported 19
months with only one patient reported, Blacks reported 44.34
months (SD = 43.17), and American Indians/Alaska Natives
reported 44.00 months (SD = 48.06).

4. Study Limitations
SEER has collected cancer data for over thirty years from
cancer registries throughout the United States; it is nationally
recognized and considered reliable source of information on
incidence, mortality, and other related variables. Although
use of SEER lends this study strength, it is limited in the
information it can provide. SEER lacks insight into many
variables, such as social and economic factors, that affect the
survival time of breast cancer patients and may explain much
of the disparities experience by more disadvantaged groups.

5. Conclusions
This study concludes that there are several factors accounting
for breast cancer survival including state, local, and individual
level factors. For example, the age of diagnosis was greatly
different for those living in Iowa compared to Georgia. This
presented a seven-year difference in disease presentation. It is
imperative to understand what differences are found in breast
cancer prevention between those two states. Additionally,
there are other factors that may account for the differences
in age of diagnosis. Even more concerning is the stark
differences in disease prognosis.
At the state and governmental level, future studies may
compare state policies, preventive breast cancer systems, and
the current state of the health care systems and their effect
on the outcome of women diagnosed with breast cancer.
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However, it may also be important for future studies to
address other demographic variables including income, education level, and health insurance status. To better understand
patient survival, primary factors affecting patient prognosis
should be addressed. These factors can be current medical
treatment and prevention regimen that affect breast cancer
diagnosis and treatment, and more indirect factors will also
affect survival. Additionally, further investigation should
be considered at the community level to determine what
specific factors prevent the receipt of preventive screening
or access to adequate care. This will inform the design and
troubleshooting of prevention and treatment efforts.
These study findings give credence to the importance of
early detection and treatment in reducing breast cancer incidence nationwide. Given the patient’s current location and
reported conditions, our findings suggest that geographical
and local characteristics affect the survival rates of breast
cancer patients. More in-depth research can help highlight
factors contributing to the disparities seen across states. State
health policies, access to health care, breast cancer screening
and awareness programs, and cultural norms may affect
screening and preventive care, which will likely affect longterm patient survival. The mean age at diagnosis ranged from
58 to 64 years, underlining the importance for following
the United States Preventive Services Task Force (USPSTF)
recommendations for biennial screening mammography for
women aged 50 to 74 years. Breast cancer takes approximately
2 to 5 years to develop; therefore, women should be screened
regularly to identify and treat precancers as well as prevent
the progression of breast cancer. The findings in this study
reinforce the importance of early detection and treatment
in reducing breast cancer. Increasing patient survival first
begins with improving screening efforts among poor and
underserved women who may be at highest risk. However,
it is important to recognize that some women, such as
those with a family history of the disease, are at risk and
may experience earlier presentations of breast cancer and
should be screened earlier than the standard guidelines
suggest. Public health and health care prevention efforts
should target the most disadvantaged communities to help
eliminate breast cancer-related health equity. For example,
Black women experience more aggressive forms of breast
cancer and are often diagnosed at early ages; therefore,
this group may require more attention in screening and
education efforts. This study showed that stage IV cancer
had the lowest survival times among all groups. The highest
survival times for Whites and American Indians/Alaska
Natives were for stage I cancers, and the highest survival
times for Blacks varied in the 5-year stratification analysis.
Furthermore, economically disadvantaged patients that lack
health insurance often do not receive adequate or appropriate
care for their diagnosis adversely affecting their prognosis.
This may include improving the treatment options for these
groups and improving screening efforts to ensure earlier disease detection. Additionally, improving outreach efforts for
programs such as NBCCEDP will help to target many underserved communities. Furthermore, high survival estimates
in New Mexico, California, and Connecticut indicate the
need to gather information about regional and environmental
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characteristics affecting the survival rates of breast cancer
patients. The combination of current knowledge and previous
research regarding predictive modeling can be used to inform
policy decisions and to plan allocation of future resources and
interventions [18–21]. As it relates to cancer prevention and
control there are several other factors that have been associated with breast cancer risk including lifestyle practices such
as alcohol and tobacco use, obesity, and physical inactivity.
Medical therapies such as high duration of hormone therapy
to treat menopause have also been associated with increased
breast cancer risk. Consistent biennial screening and genetic
testing for those who are genetically predisposed to breast
cancer have also been strongly linked to reducing breast
cancer risk and should be encouraged. However, many at risk
groups also face issues of alcohol and tobacco use, poor diet,
obesity, and physical inactivity which increase their risk of
cancer. Therefore, these lifestyle changes should be addressed
in more disadvantaged groups to help prevent and control
the incidence of cancer. Additionally, women in these groups
often experience no or inadequate health insurance coverage
that provides affordable screening options. Therefore, there
is more need to provide affordable screening options in
minority and socioeconomically disadvantaged communities
as well as providing nutrition and fitness counseling services
that encourage healthy lifestyle choices that are reasonable
and practical for economically disadvantaged communities
that face greater barriers and poorer breast cancer outcomes.
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